From a Concept on a Chalkboard to Gapmer Antisense
Open Access
- 29 September 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (40) , 60497-60504
Abstract
Gapmer antisense oligonucleotides emerged from our efforts to improve the stability, affinity, and potency of early phosphodiester and phosphorothioate (PS) antisense oligonucleotides. Working with Paul Zamecnik during the late 1980s and early 1990s, I witnessed the transition from a simple steric-block model of antisense action to the recognition of RNase H as the central driver of potency. Our systematic exploration of backbone and sugar modifications revealed the limitations of single-chemistry approaches and led to the development of hybrid antisense constructs that combined deoxyribonucleotide with 2′-modified ribonucleotide segments, all PS-modified. Such designs later became known as gapmers and provided enhanced stability, improved affinity, and efficient RNase H activation. Although our initial efforts with phosphorothioate oligonucleotides faltered in the clinic, continued refinement of the hybrid designs ultimately enabled the development of multiple approved drugs. Here I describe how a concept sketched on a chalkboard evolved into a widely adopted therapeutic platform.Keywords
This publication has 60 references indexed in Scilit:
- Transient Cyclic Structured Oligonucleotide Designs for Therapeutic ApplicationsCurrent Protocols, 2026
- Effects of synthetic oligonucleotides on human complement and coagulation∗Biochemical Pharmacology, 1997
- Hybrid oligonucleotides: Synthesis, biophysical properties, stability studies, and biological activityBioorganic & Medicinal Chemistry, 1996
- Effect of different chemically modified oligodeoxynucleotides on immune stimulationBiochemical Pharmacology, 1996
- Novel enzymatic and immunological responses to oligonucleotidesToxicology Letters, 1995
- Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administrationBiochemical Pharmacology, 1995
- Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*Clinical Pharmacology & Therapeutics, 1995
- Sequence‐dependent hydrolysis of RNA using modified oligonucleotide splints and RNase HFEBS Letters, 1987
- Isolation and characterization of dinucleoside tetra- and tri-phosphates formed in the presence of lysyl-sRNA synthetaseBiochemical and Biophysical Research Communications, 1966
- THE ENZYMATIC TRANSFER OF HYDROGENJournal of Biological Chemistry, 1953